Homoharringtonine (HHT), currently FDA-approved for leukemia treatment, selectively eliminates senescent cells in white adipose tissue by binding to heat shock protein HSPA5. The compound prevented diet- and age-induced obesity and insulin resistance in male mice while extending lifespan in both progeroid and naturally aged animals. This represents a significant advancement in the senotherapy field, which has struggled to find drugs that can selectively kill senescent cells without harming healthy tissue. The discovery emerges from systematic screening of 2,150 existing drugs, demonstrating the power of drug repositioning for aging research. What makes this particularly compelling is that HHT is already clinically available, potentially accelerating translation to human trials. The metabolic focus is crucial since senescent fat cells drive systemic inflammation and insulin resistance — hallmarks of aging. However, the study's limitation to male mice and focus on adipose tissue leaves questions about broader applicability and sex-specific effects. While promising, this finding requires validation in human studies before drawing conclusions about therapeutic potential. The mechanistic clarity around HSPA5 targeting provides a clear path for further development of more specific senotherapeutic compounds.